Rising Health Care Costs and Life-Cycle Management in the Pharmaceutical Market

article has not abstract

Vyšlo v časopise: Rising Health Care Costs and Life-Cycle Management in the Pharmaceutical Market. PLoS Med 10(6): e32767. doi:10.1371/journal.pmed.1001461
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001461

Souhrn

article has not abstract

Zdroje

1. VernazN, HallerG, GirardinF, HuttnerB, CombescureC, et al. (2013) Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. PLoS Med 10: e1001460 doi:10.1371/journal.pmed.1001460

2. KapczynskiA, ParkC, SampatB (2012) Polymorphs and prodrugs and salts (oh my!): an empirical analysis of “secondary” pharmaceutical patents. PLoS ONE 7(12): e49470 doi:10.1371/journal.pone.0049470

3. GrandeD (2012) The cost of drug coupons. JAMA 307(22): 2375–2376.

4. KesselheimAS, MurtaghL, MelloMM (2011) “Pay-for-delay” settlements of disputes over pharmaceutical patents. N Engl J Med 365(15): 1439–1445.

5. KesselheimAS (2007) Intellectual property policy in the pharmaceutical sciences: the effect of inappropriate patents and market exclusivity extensions on the health care system. AAPS Journal 9: Article 33.

6. SilvermanE (2008) Schering-Plough wines & dines Zetia docs. Pharmalot 11 Mar 2008. Available: http://www.pharmalive.com/schering-plough-wines-dines-zetia-docs. Accessed 3 May 2013.

7. KesselheimAS, FischerMA, AvornJ (2006) Extensions of intellectual property rights and delayed adoption of generic drugs: effects on Medicaid spending. Health Affairs 25: 1637–1647.

8. HarrisG, ThomasK (2013) Low-cost drugs in poor nations get a lift in Indian court. New York Times 1 April 2013 A1.